| |
Is your lab informatics platform science-aware™️? Many of today's LIMS and ELNs cannot flex without tedious coding or SQL. Read our guide and discover five key markers of a modern lab platform that drives productivity and simplifies life in the lab.
|
|
Today's Big NewsApr 26, 2023 |
| By James Waldron Roche executives have insisted that they haven’t given up on anti-TIGIT checkpoint inhibitors, even as they dodged questions about whether their candidate has flunked yet another phase 3 trial. |
|
|
|
By Nick Paul Taylor Roche no longer sees the magic in MAGE-A4. The Swiss drugmaker signaled a retreat from the TCR T-cell target in its first quarter results by putting a pair of phase 1 solid tumor programs out to pasture. |
By Fraiser Kansteiner As a potential approval for GSK's RSV vaccine nears in the U.S., the company has “begun disease awareness activities where needed and our launch preparations are well underway,” chief commercial officer Luke Miels said Wednesday. On the same day, the European Medicines Agency endorsed the shot, sending it to the European Commission for a rubber stamp. |
By Conor Hale The pledge comes as the DNA sequencing giant is embroiled in a proxy fight with activist investors over its board of directors. |
|
Thursday, May 4, 2023 | 11am ET / 8am PT Join industry experts for this insightful webinar to learn more about enzyme inhibition studies. We’ll explore how these studies drive informed decisions for drug developers, frequently asked questions from sponsors, recommendations for achieving successful regulatory submission, and more. Register now.
|
|
By Andrea Park Another 6,000 3M employees are set to be laid off, joining the 2,500 job cuts announced earlier this year. |
By Zoey Becker Johnson & Johnson is the latest drugmaker to land in Doctors Without Borders' hot seat. The organization is calling on the company to allow generics to its tuberculosis med Sirturo in countries with a high burden of the infectious disease. |
By Annalee Armstrong SAB Biotherapeutics vowed to plow on through the fields with a cow-plasma-based COVID-19 treatment after the National Institutes of Health (NIH) dropped out last year. Now, the data harvest is complete and the government’s omicron-based concerns appear to be justified. |
By Gabrielle Masson Orbital Therapeutics has raised an eye-popping $270 million for its collection of RNA tools and pursuit of next-gen medicines, while also looping in two new execs. |
By Fraiser Kansteiner In April, GSK “permanently” discontinued enrollment in ZEST, a late-stage study from 2021 aiming to recruit 800 patients with either HER2-negative, BRCA-mutated breast cancer or triple-negative breast cancer with molecular disease. |
By Andrea Park Nearly a year-and-a-half after receiving a warning letter from the FDA detailing a list of quality control issues at the Los Angeles-area headquarters of its diabetes business, Medtronic said it has finally resolved all of the regulator’s concerns. |
By Kevin Dunleavy The passage of the Inflation Reduction Act was a resounding victory for congressional Democrats over Big Pharma. But on Capitol Hill, it seems to have only whetted the appetite for more reform. |
By Max Bayer Flagship Pioneering-founded Evelo is moving on from its lead asset after additional dose cohort data in patients with atopic dermatitis mirrored past failures, with more job cuts on the way. |
By Angus Liu AstraZeneca and Merck & Co.’s Lynparza may have claimed a broad trial success—and European approval—in prostate cancer, but the FDA has its reservations. In new briefing documents, the agency argues the med is only appropriate for a small subset of patients. |
By Andrea Park After two straight years of quarterly sales growth, that trend hasn’t yet gone out of style for Boston Scientific. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out, register today.
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
